In Pulmonary arterial hypertension (PAH) WHO Class III or IV
Tracleer stands alone
Bosentan (BOZENTAN) is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH under the trade name Tracleer.
Brand name: Tracleer
Generic name/category: Bosentan, Endothelin receptor antagonists
Company: Actelion
Country/Market: USA, North America
Indication(s)/use: Pulmonary arterial hypertension (PAH)
Target: Healthcare Professionals (HCP)
Tagline: A cornerstone of oral therapy
Medium: Print ad
Size/duration: single-page
Publication/Aired: Chest – September 2009
To see all of this brand's ads on AdPharm, click here
1 views
Sep 19, 2009
Visit AdPharm.net for more pharmaceutical ads
Tags: cardiovascular, endothelin, low-angle_view, pah, pharma, solid, the-treatment, united-states, usa
Business Week – Drug Marketing
Business Week – Pharma Marketing
Cafe Pharma
Clinical Trials.gov
FDA on Twitter
Pharma Live
Pharma Voice